Patricia Oliver, Ph.D., is a pharmaceutical veteran nearly three decades of experience encompassing all aspects of CMC. A proven leader at driving CMC activities, Patricia has led the strategic and operational management of CMC teams to produce targeted therapeutics in compliance with the highest quality assurance/regulatory standards. She has authorized dozens of regulatory documents (INDs, IMPDs, NDAs, ANDAs) and has successfully managed the development of both small molecule and biologics drug candidates from lead optimization to commercialization. She has helped bring to market Ritonavir®, Kaletra®, Telaprevir® and Glatopa® and has multiple papers and patents reflecting her contributions to these and many other drug candidates.
Patricia received her Ph.D. in organic chemistry from the University of Wisconsin-Madison and her bachelor’s degree in chemistry/pre-medicine from the College of the Holy Cross.